TaiMed Biologics
TaiMed is a world class biotechnology company, we are providing comprehensive process development and CDMO service.
TaiMed is a world class biotechnology company, we are providing comprehensive process development and CDMO service.
TaiMed Biologics is a Taiwan-based biotechnology company founded in 2007. It has established itself as a leading biopharmaceutical developer and manufacturer, with a significant focus on monoclonal antibodies (mAb). The company has achieved a notable milestone by successfully developing and commercially launching the first and only mAb for HIV treatment in the US and Europe under the brand name Trogarzo®. TaiMed's expertise extends to offering comprehensive Contract Development and Manufacturing Organization (CDMO) services, catering to the needs of biopharmaceutical companies in propelling mAb molecules from development to market launch. The company has garnered a noteworthy $22.00M Series B investment on 31 March 2010, with funding from Taiwan Development Fund and YFY Biotech Management Company. Its dedication to providing comprehensive process development and CDMO service reflects TaiMed's positioning as a world-class biotechnology company. With a strong foundation in biopharma, biotechnology, and manufacturing industries, TaiMed Biologics stands at the forefront of advancing innovative solutions in the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $22.00M | 2 | Taiwan Development Fund, YFY Biotech Management Company | 31 Mar 2010 |
No recent news or press coverage available for TaiMed Biologics.
We care about your data, and we'd love to use cookies make your experience better.
